Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from PainReform ( (PRFX) ) is now available.
On December 2, 2025, PainReform Ltd. announced the commencement of its development plan for OcuRing™-K, a sustained-release ocular therapy designed for post-cataract surgery pain and inflammation management. This initiative marks a significant step in addressing the limitations of traditional eye-drop regimens by offering a drop-less, intraoperatively administered solution. The development plan follows PainReform’s majority investment in LayerBio and aims to advance OcuRing-K into Phase II clinical trials, potentially impacting the multi-billion-dollar global cataract surgery market by improving treatment consistency and patient compliance.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Underperform.
PainReform faces substantial financial hurdles, primarily due to its lack of revenue and persistent losses, making its financial performance the most significant negative factor. Technical analysis reflects a neutral to slightly bearish outlook, while valuation metrics underscore the company’s financial struggles with a negative P/E ratio. Overall, the stock presents high risks without notable strengths to offset these concerns.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PainReform Ltd. is a company focused on reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform. The company specializes in pharmaceutical programs that leverage a proprietary extended-release drug-delivery system for prolonged post-surgical pain relief, minimizing the need for repeated dosing and reducing opioid reliance. Additionally, PainReform provides advanced software solutions for energy consumption optimization in solar-integrated environments, reflecting its strategic commitment to healthcare and sustainable energy.
Average Trading Volume: 366,697
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.89M
See more insights into PRFX stock on TipRanks’ Stock Analysis page.